Skip to main content
. 2013 Sep 22;33(1):39–47. doi: 10.1007/s10067-013-2392-2

Fig. 4.

Fig. 4

Kaplan–Meier curves for time to discontinuation for each biologic. Withdrawal was due to a insufficient clinical efficacy (insufficiency) and b adverse events. Retention rates were compared using the log-rank test among groups. ABT abatacept, ADA adalimumab, TCZ tocilizumab